SK3 Group (OTC Pink: SKTO) Announces Clarification Regarding Press Release From Aventura Equities Dated February 26, 2014
February 27 2014 - 9:50AM
Marketwired
SK3 Group (OTC Pink: SKTO) Announces Clarification Regarding Press
Release From Aventura Equities Dated February 26, 2014
LOS ANGELES, CA--(Marketwired - Feb 27, 2014) - SK3
Group (OTC Pink: SKTO) wishes to clarify certain statements made by
Aventura Equities, Inc. ("Aventura") in its press release dated
February 26, 2014 ("the Aventura Equities Release").
We have the utmost respect for our business partners at Aventura
Equities. However, the Aventura Equities Release was made by
the management of Aventura Equities without any prior notice,
involvement, or approval of SKTO's management, which could have
made the release more clear had it been obtained in advance.
Aventura has not acquired Berkeley Bio-Organic Research
Laboratory ("Berkeley Bio"). Berkeley Bio remains a
wholly-owned subsidiary of SKTO. In addition, although the
transaction referenced resulted in Aventura receiving the rights to
the intellectual property in the proprietary technology, processes,
formulations, and marks of Berkeley Bio that have already been
developed, SKTO remains, and will remain, the exclusive licensee of
such intellectual property. The announced agreement/transfer
does not permit Aventura to license others to use this intellectual
property. In addition, the agreement announced by Aventura
Equities does not cover future intellectual property developed by
Berkeley Bio which will inure to the benefit of SKTO unless
otherwise agreed. We have become aware of incorrect
speculation that somehow this announcement impinges upon the rights
of SKTO to its use of the Berkeley Bio technology, and that is
simply incorrect.
"We continue to be a part of the SKTO family, and remain pleased
that we are," said Berkeley Bio-Organic Research Laboratory
Director David Hoye. "We remain a subsidiary company of SKTO and
SKTO continues to be the sole and exclusive licensee of the
proprietary technology, processes, and formulations developed by
Berkeley Bio, and we look forward to remaining so for the long
term. I would not be involved if it were otherwise."
About SKTO SK3 is a healthcare logistics and fulfillment
consultancy focused on the delivery of alternative care and
medicine. With seasoned management, breakthrough technology and
best practices, SK3 brings standardization and transparency to this
rapidly growing segment of the alternative care field.
FDA Statement The statements in this document have not been
evaluated or approved by the FDA. The products and statements
referenced in this document are not intended to diagnose, treat,
cure, or prevent any disease.
Safe Harbor Statement This press release contains
forward-looking statements within the meaning of Section 27A of the
Securities Act of 1933 and Section 21E of the Securities Exchange
Act of 1934. These forward-looking statements are based on the
current plans and expectations of management and are subject to a
number of uncertainties and risks that could significantly affect
the company's current plans and expectations, as well as future
results of operations and financial condition. A more extensive
listing of risks and factors that may affect the company's business
prospects and cause actual results to differ materially from those
described in the forward-looking statements can be found in the
reports and other documents filed by the company with the
Securities and Exchange Commission. The company undertakes no
obligation to publicly update or revise any forward-looking
statements, whether as a result of new information, future events
or otherwise.
Contact: Medical Greens investors@medicalgreens.com Investor
Relations
SK3 (CE) (USOTC:SKTO)
Historical Stock Chart
From Mar 2024 to Apr 2024
SK3 (CE) (USOTC:SKTO)
Historical Stock Chart
From Apr 2023 to Apr 2024